SNWV SANUWAVE Health Inc

SANUWAVE Attends 3rd Annual Leaders in Wound Healing Conference

SANUWAVE Attends 3rd Annual Leaders in Wound Healing Conference

EDEN PRAIRIE, MN, April 26, 2023 (GLOBE NEWSWIRE) -- via – SANUWAVE, a leading medical technology company focused on the development and commercialization of non-invasive, regenerative medicine solutions, attended the 3rd Annual Leaders in Wound Healing Conference on April 18th and 19th in New Orleans, LA.

The Leaders in Wound Healing Conference is an invitation-only event that brings together leaders in the field of wound healing to exchange ideas and discuss innovative technology. SANUWAVE was honored to be among the select group of attendees and to have the opportunity to contribute to the important discussions on the future of wound care.

"We are thrilled to have been invited to attend the Leaders in Wound Healing Conference," said Kevin Richardson II, Chairman and CEO of SANUWAVE. "As a company dedicated to advancing the field of regenerative medicine, this conference is an ideal venue for us to share our expertise and learn from other thought leaders."

Dr. Jonathan Johnson, also known as “Dr. Wounds”, from Comprehensive Wound Care Services | Capital Aesthetic and Laser Center, Washington, DC delivered an informative and compelling presentation;  “The Clinical Benefits of Using UltraMIST to treat VLU’s”.

Dr. Johnson hosts an educational series, “Wound Care Wednesdays” with a recent.

SANUWAVE is committed to developing and commercializing non-invasive, regenerative medicine solutions for a range of medical conditions, including wound healing. The company's groundbreaking technology has been shown to accelerate the healing of chronic wounds, leading to improved patient outcomes and a reduced burden on the healthcare system.

"We are proud to be at the forefront of regenerative medicine and to have the opportunity to share our innovative solutions with other leaders in the field," said Richardson. "We look forward to continuing to collaborate with other attendees to advance the science and improve patient care."

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.  For more information, visit

CONTACT:

Kevin Richardson, II

Chief Executive Officer





EN
26/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SANUWAVE Health Inc

 PRESS RELEASE

Sanuwave Health to Uplist to the Nasdaq Global Market

Sanuwave Health to Uplist to the Nasdaq Global Market Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025 EDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced today that its common stock has been approved for listing on the Nasdaq Global Market (“Nasdaq”). Trading on Nasdaq is expected to commence at the market open on March 7, 2025, with shares continuing to trade under the ticker symbol “SNWV.” The Company’s shares will...

 PRESS RELEASE

SANUWAVE Health to Participate in 37th Annual Roth Conference

SANUWAVE Health to Participate in 37th Annual Roth Conference EDEN PRAIRIE, Minn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that Morgan Frank, Chief Executive Officer, will participate in the 37th Annual Roth Conference to be held on March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. Management will be available for one-on-one meetings throughout the conference. Interested investors should contact their Roth representative or email to sched...

 PRESS RELEASE

SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Resu...

SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results Q3 2024 revenues were $9.4 million, up 89% from Q3 2023. This was an all-time quarterly record for the Company. Q3 2024 gross margin was 75.5%, vs 71.5% in Q3 2023 GAAP Operating Income was $2.0 million Company provides guidance for revenue growth of 40-50% for Q4 2024 versus Q4 2023 EDEN PRAIRIE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial ...

 PRESS RELEASE

SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (E...

SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial Results EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 8, 2024, at 8:30 AM (ET) to present its Q3 2024 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-97...

 PRESS RELEASE

SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and...

SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering 1-for-375 reverse stock split effective at market open today Exchanged $43.2 million in principal amount of convertible notes and warrants previously exercisable for approximately 1.7 billion pre-split shares for approximately 4.0 million post-split shares Closed $10.3 million equity only PIPE offering at $8.25 per share of common stock led by certain institutional investors, including AWM Investment Company, Inc., the investment adviser of the Special Situations Funds and with participation from Ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch